Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Immutep Ltd ( (AU:IMM) ).
Immutep Limited has released its corporate governance statement for the financial year ending 30 June 2025, which is available on their website. The statement, approved by the board, outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting its commitment to transparency and accountability in its operations. This disclosure is crucial for stakeholders as it ensures compliance with governance standards, potentially impacting the company’s reputation and investor confidence.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited operates in the biotechnology industry, focusing on the development of immunotherapy treatments. The company is primarily engaged in advancing its pipeline of products aimed at modulating the immune system to combat cancer and autoimmune diseases.
Average Trading Volume: 2,429,062
Technical Sentiment Signal: Buy
Current Market Cap: A$448.9M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.